Auinger P - Search Results

1

BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.

Fischer DL, Auinger P, Goudreau JL, Cole-Strauss A, Kieburtz K, Elm JJ, Hacker ML, Charles PD, Lipton JW, Pickut BA, Sortwell CE. Fischer DL, et al. Among authors: auinger p. Neurotherapeutics. 2020 Oct;17(4):1785-1795. doi: 10.1007/s13311-020-00965-9. Epub 2020 Nov 19. Neurotherapeutics. 2020. PMID: 33215284 Free PMC article. Clinical Trial.

2

Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.

Fischer DL, Auinger P, Goudreau JL, Paumier KL, Cole-Strauss A, Kemp CJ, Lipton JW, Sortwell CE. Fischer DL, et al. Among authors: auinger p. Parkinsonism Relat Disord. 2018 Aug;53:70-75. doi: 10.1016/j.parkreldis.2018.05.003. Epub 2018 May 9. Parkinsonism Relat Disord. 2018. PMID: 29759928

3

Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.

Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, Kieburtz K; NET-PD Investigators. Constantinescu R, et al. Among authors: auinger p. Mov Disord. 2014 Feb;29(2):263-5. doi: 10.1002/mds.25734. Epub 2013 Dec 3. Mov Disord. 2014. PMID: 24323565 Free PMC article. Clinical Trial.

4

The relationship between uric acid levels and Huntington's disease progression.

Auinger P, Kieburtz K, McDermott MP. Auinger P, et al. Mov Disord. 2010 Jan 30;25(2):224-8. doi: 10.1002/mds.22907. Mov Disord. 2010. PMID: 20063429 Free PMC article.

5

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M. McGarry A, et al. Among authors: auinger p. J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241. J Huntingtons Dis. 2017. PMID: 28826192 Clinical Trial.

6

Levodopa response in early Parkinson's disease.

Hauser RA, Auinger P, Oakes D; Parkinson Study Group. Hauser RA, et al. Among authors: auinger p. Mov Disord. 2009 Dec 15;24(16):2328-36. doi: 10.1002/mds.22759. Mov Disord. 2009. PMID: 19908302

7

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease.

McGarry A, Auinger P, Kieburtz KD, Bredlau AL, Hersch SM, Rosas HD. McGarry A, et al. Among authors: auinger p. Neurol Clin Pract. 2022 Apr;12(2):131-138. doi: 10.1212/CPJ.0000000000001161. Neurol Clin Pract. 2022. PMID: 35747889 Free PMC article.

8

Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.

McGarry A, Auinger P, Kieburtz K, Geva M, Mehra M, Abler V, Grachev ID, Gordon MF, Savola JM, Gandhi S, Papapetropoulos S, Hayden M. McGarry A, et al. Among authors: auinger p. J Huntingtons Dis. 2020;9(2):173-184. doi: 10.3233/JHD-190393. J Huntingtons Dis. 2020. PMID: 32508327 Clinical Trial.

9

Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.

Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R; Parkinson Study Group-DATATOP Investigators. Christine CW, et al. Among authors: auinger p. Mov Disord. 2018 May;33(5):762-770. doi: 10.1002/mds.27301. Epub 2018 Mar 6. Mov Disord. 2018. PMID: 29508904 Clinical Trial.

10

Determination of minimal clinically important change in early and advanced Parkinson's disease.

Hauser RA, Auinger P; Parkinson Study Group. Hauser RA, et al. Among authors: auinger p. Mov Disord. 2011 Apr;26(5):813-8. doi: 10.1002/mds.23638. Epub 2011 Mar 24. Mov Disord. 2011. PMID: 21437987 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters